Rainier Therapeutics, Inc.

22 articles about Rainier Therapeutics, Inc.

• Rainier Therapeutics Announces Vofatamab FIERCE-22 Data Accepted for Presentation at ESMO 2019 Annual Congress

  7/29/2019

  Updated Interim Analysis from FIERCE-22 Phase 2 Trial in Metastatic Bladder Cancer

• Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)

  6/3/2019

  Rainier Therapeutics, Inc., a privately held clinical stage drug development company, today announced the first interim analysis results from its ongoing FIERCE-22 trial of vofatamab in patients with metastatic bladder cancer.

• Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell Activation

  5/20/2019

  Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the presentation of data from its FIERCE-22 trial where vofatamab, the company’s lead therapeutic stimulates an increase in immune cell activation in patients with metastatic bladder cancer.

• Rainier Therapeutics Announces Upcoming Oral and Poster Presentation on Vofatamab at AACR Bladder Cancer Conference

  5/9/2019

  Rainier Therapeutics, Inc. announced that an abstract related to its FIERCE-22 trial of the company’s lead therapeutic, vofatamab, has been accepted for an oral and poster presentation at the upcoming 2019 American Association for Cancer Research (AACR) Bladder Cancer;

• Rainier Therapeutics Announces Appointment of Gary Christianson as Chief Technical Officer

  5/1/2019

  Rainier Therapeutics, Inc., a privately held clinical stage drug development company, today announced the appointment of Gary Christianson, PE, as Chief Technical Officer.

• Rainier Therapeutics Announces Vofatamab Data Accepted for Presentation at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

  4/25/2019

  Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that abstracts related to trials of the company’s lead therapeutic, vofatamab, have been accepted for presentation at the upcoming 2019 American Society for Clinical Oncology (ASCO) Annual Meeting, which will take place May 31 to June 4, 2019 in Chicago, Illinois.

• Rainier Therapeutics to Participate in the SVB Leerink Global Healthcare Conference

  2/21/2019

  Rainier Therapeutics, Inc. announced that Scott Myers, Chairman and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 1:30 p.m. ET at the Lotte New York Palace in New York City.

• Rainier Therapeutics Presents Data on Vofatamab in Patients with Advanced Urothelial Cell Carcinoma (Bladder Cancer) Previously Treated with Chemotherapy at ASCO GU 2019

  2/15/2019

  Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the presentation of preliminary data from its Phase 2 trial of vofatamab, a fibroblast-growth-factor-receptor 3 (FGFR3) targeted antibody, at the 2019 ASCO Genitourinary Cancers Symposium in San Francisco.

• Rainier Therapeutics Announces Oral Abstract Presentation on Fierce 21 Phase 2 Trial of Vofatamab in Metastatic Urothelial Cell Carcinoma (Bladder Cancer) at the 2019 ASCO Genitourinary Cancers Symposium

  1/22/2019

  Rainier Therapeutics, Inc. today announced that data from its ongoing Phase 2 trial of its FGFR3-targeted antibody vofatamab will be presented at the upcoming 2019 ASCO Genitourinary Cancers Symposium taking place February 14-16, 2019 at the Moscone West Building in San Francisco.

• Rainier Therapeutics Announces Fast Track Designation Granted by FDA for Vofatamab in Treatment of FGFR3-Positive Urothelial Cell Carcinoma (Bladder Cancer)

  1/7/2019

  The FDA’s Fast Track designation is a process to facilitate development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

• Rainier Therapeutics Expands Leadership Team to Prepare for Late-Stage Clinical Trials

  1/3/2019

  Rainier Therapeutics, Inc. today announced the expansion of its team with appointments spanning regulatory, medical affairs, corporate development and legal affairs, as well as pharmacovigilance.

• BioClin Therapeutics Announces Name Change to Rainier Therapeutics

  11/27/2018

  The new name will be implemented immediately

• BioClin Therapeutics to Participate in BTIG Biotech Conference

  10/22/2018

  Dr. Graeme Currie, Ph.D., Chief Operating Officer, will participate in a panel “Targeted Oncology Therapies – Material Advancements, Intriguing Potential” at 1:30 p.m. ET on Thursday, October 25th.

• 

  BioSpace Movers and Shakers for Oct. 15

  10/15/2018

  Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.

• BioClin Therapeutics Announces New Leadership to Advance Late-Stage Bladder Cancer Development Program

  9/18/2018

  BioClin Therapeutics, Inc. today announced the appointment of Scott Myers as Chief Executive Officer, and Julie Eastland as Chief Financial Officer and Chief Business Officer. Mr. Myers will also continue in his role as company Chairman.

• BioClin Therapeutics Appoints Scott Myers as Chairman to its Board of Directors

  6/26/2018

  BioClin Therapeutics, Inc., a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet medical need, announced today the appointment of Scott D. Myers as chairman of Board of Directors.

• BioClin Therapeutics, Inc. Announces Poster Presentation of B-701 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/17/2018

  BioClin Therapeutics, Inc., a clinical stage drug development company announced today that data will be presented from its ongoing Phase 1b/2 study of B-701, a first-in-class anti-fibroblast growth factor receptor 3 (FGFR3) monoclonal antibody, plus docetaxel for metastatic bladder cancer at a poster session at the 2018 American Society for Clinical Oncology (ASCO) meeting being held June 1-5, 2018 in Chicago, IL.

• BioClin Therapeutics, Inc., Completes $50 Million Series B Financing with Addition of New Investors

  5/9/2018

  Series B financing to broaden its clinical development activities.

• 

  Bay Area's BioClin Taps Gilead R&D Exec as New CMO

  1/10/2018

  This build out of the executive team follows the closing of a $30 million Series B financing announced last year.

• Bay Area's BioClin Therapeutics Nabs $30 Million Series B for Bladder Cancer Med

  3/22/2017